New drug cocktail aims to boost myeloma treatment before and after transplant

NCT ID NCT04802356

Ongoing Disease control Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called belantamab mafodotin (Blenrep) combined with standard therapy (VRd) in 50 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and helps control the disease before and after transplant. Participants receive the drugs in cycles, then a transplant, then more treatment to keep the cancer in check.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (Blenrep) combined with bortezomib, lenalidomide, and dexamethasone (VRd)
What this could lead to: If successful, this combination could improve response rates and extend disease control for newly diagnosed multiple myeloma patients undergoing transplant.
What could go wrong: This is an early-phase (Phase 2) trial with only 50 participants, so results may not apply to all patients. The drug combination carries risks like eye problems and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Complejo Universitario Hospitalario de Santiago

Santiago de Compostela, Galicia, 15706, Spain
Hospital General Universitario Morales Meseguer

Murcia, 30008, Spain
Hospital Gregorio Marañon

Madrid, Madrid, 28007, Spain
Hospital Infanta Leonor

Madrid, Spain
Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, 07198, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, 39008, Spain
Hospital Universitario de Gran Canaria Dr. Negrín

Las Palmas de Gran Canaria, Spain
Hospital Universitario de Salamanca

Salamanca, Castille and León, 37007, Spain
Hospital Universitario y Policlínico de la Fe

Valencia, Valencia, 46026, Spain
Hospital Virgen de la Arrixaca

Murcia, Spain
Hospital de Cabueñes

Gijón, Principality of Asturias, 33394, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.